Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Targeting the EGFR-family for therapy: biological challenges and clinical perspective.

Patel R, Leung HY.

Curr Pharm Des. 2012;18(19):2672-9. Review.

PMID:
22390755
2.

A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.

Claus J, Patel G, Ng T, Parker PJ.

Biochem Soc Trans. 2014 Aug;42(4):831-6. doi: 10.1042/BST20140043. Review.

PMID:
25109965
3.

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Baselga J, Arteaga CL.

J Clin Oncol. 2005 Apr 10;23(11):2445-59. Epub 2005 Mar 7. Review. Erratum in: J Clin Oncol. 2005 Sep 1;23(25):6281.

PMID:
15753456
4.

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

Hsieh AC, Moasser MM.

Br J Cancer. 2007 Aug 20;97(4):453-7. Epub 2007 Jul 31. Review.

5.

The role of ErbB inhibitors in trastuzumab resistance.

Miller KD.

Oncologist. 2004;9 Suppl 3:16-9. Review.

6.

Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics.

Hervent AS, De Keulenaer GW.

Int J Mol Sci. 2012 Sep 26;13(10):12268-86. doi: 10.3390/ijms131012268. Review.

7.

The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?

Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M, McCubrey JA.

Expert Opin Ther Targets. 2005 Oct;9(5):1009-30. Review.

PMID:
16185155
8.

Targeting ErbB receptors in high-grade glioma.

Berezowska S, Schlegel J.

Curr Pharm Des. 2011;17(23):2468-87. Review.

PMID:
21827413
9.

Emerging strategies for ErbB ligand-based targeted therapy for cancer.

Tsujioka H, Yotsumoto F, Shirota K, Horiuchi S, Yoshizato T, Kuroki M, Miyamoto S.

Anticancer Res. 2010 Aug;30(8):3107-12. Review.

PMID:
20871027
10.
11.

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

Arteaga CL, Engelman JA.

Cancer Cell. 2014 Mar 17;25(3):282-303. doi: 10.1016/j.ccr.2014.02.025. Review.

12.

Epidermal growth factor receptor as a major anticancer drug target.

Caponigro F, Milano A, Ottaiano A, Iaffaioli RV.

Expert Opin Ther Targets. 2006 Dec;10(6):877-88. Review.

PMID:
17105374
13.
14.

Therapeutic targeting of the epidermal growth factor receptor in human cancer.

Dhomen NS, Mariadason J, Tebbutt N, Scott AM.

Crit Rev Oncog. 2012;17(1):31-50. Review.

PMID:
22471663
15.

Targeting the ERBB family in cancer: couples therapy.

Tebbutt N, Pedersen MW, Johns TG.

Nat Rev Cancer. 2013 Sep;13(9):663-73. doi: 10.1038/nrc3559. Epub 2013 Aug 16. Review.

PMID:
23949426
16.

Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.

Bellmunt J, Hussain M, Dinney CP.

Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S85-104. Review.

PMID:
12850530
17.

ADAM proteases, ErbB pathways and cancer.

Zhou BB, Fridman JS, Liu X, Friedman SM, Newton RC, Scherle PA.

Expert Opin Investig Drugs. 2005 Jun;14(6):591-606. Review.

PMID:
16004590
18.

Targeting the EGFR signaling pathway in cancer therapy.

Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK.

Expert Opin Ther Targets. 2012 Jan;16(1):15-31. doi: 10.1517/14728222.2011.648617. Epub 2012 Jan 12. Review.

19.

Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis.

Grandal MV, Madshus IH.

J Cell Mol Med. 2008 Sep-Oct;12(5A):1527-34. doi: 10.1111/j.1582-4934.2008.00298.x. Epub 2008 Mar 4. Review.

20.

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.

Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM.

Oncogene. 2008 Jun 26;27(28):3944-56. doi: 10.1038/onc.2008.19. Epub 2008 Feb 25.

Supplemental Content

Support Center